Literature DB >> 20360387

CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor alpha by cAMP.

Sophie Carascossa1, Peter Dudek, Bruno Cenni, Pierre-André Briand, Didier Picard.   

Abstract

The estrogen receptor alpha (ERalpha) is activated as a transcription factor by both estrogen and a large variety of other extracellular signals. The mechanisms of this ligand-independent activation, notably by cAMP signaling, are still largely unknown. We now close the gap in the signaling pathway between cAMP and ERalpha. Whereas the direct phosphorylation of ERalpha by the cAMP-activated protein kinase A (PKA) is dispensable, the phosphorylation of the coactivator-associated arginine methyltransferase 1 (CARM1) by PKA at a single serine is necessary and sufficient for direct binding to the unliganded hormone-binding domain (HBD) of ERalpha, and the interaction is necessary for cAMP activation of ERalpha. Sustained PKA activity promoting a constitutive interaction may contribute to tamoxifen resistance of breast tumors. Binding and activation involve a novel regulatory groove of the ERalpha HBD. As a result, depending on the activating signal, ERalpha recruits different coactivator complexes to regulate alternate sets of target genes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20360387      PMCID: PMC2849127          DOI: 10.1101/gad.568410

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  59 in total

Review 1.  Chaperoning steroid hormone action.

Authors:  Didier Picard
Journal:  Trends Endocrinol Metab       Date:  2006-06-27       Impact factor: 12.015

Review 2.  Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response.

Authors:  Michael G Rosenfeld; Victoria V Lunyak; Christopher K Glass
Journal:  Genes Dev       Date:  2006-06-01       Impact factor: 11.361

Review 3.  Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state.

Authors:  Kelly A Green; Jason S Carroll
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

Review 4.  Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation.

Authors:  David M Lonard; Bert W O'malley
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

5.  Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells.

Authors:  Sandra Cascio; Viviana Bartella; Cecilia Garofalo; Antonio Russo; Antonio Giordano; Eva Surmacz
Journal:  J Biol Chem       Date:  2006-12-13       Impact factor: 5.157

6.  Functional insights from structures of coactivator-associated arginine methyltransferase 1 domains.

Authors:  Nathalie Troffer-Charlier; Vincent Cura; Pierre Hassenboehler; Dino Moras; Jean Cavarelli
Journal:  EMBO J       Date:  2007-09-20       Impact factor: 11.598

7.  CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1.

Authors:  Seth Frietze; Mathieu Lupien; Pamela A Silver; Myles Brown
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  Phosphorylation-mediated inactivation of coactivator-associated arginine methyltransferase 1.

Authors:  Ken Higashimoto; Peter Kuhn; Dhaval Desai; Xiaodong Cheng; Wei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-17       Impact factor: 11.205

9.  PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1.

Authors:  Wilbert Zwart; Alexander Griekspoor; Valeria Berno; Kim Lakeman; Kees Jalink; Michael Mancini; Jacques Neefjes; Rob Michalides
Journal:  EMBO J       Date:  2007-07-12       Impact factor: 11.598

10.  Insights into histone code syntax from structural and biochemical studies of CARM1 methyltransferase.

Authors:  Wyatt W Yue; Markus Hassler; S Mark Roe; Vivienne Thompson-Vale; Laurence H Pearl
Journal:  EMBO J       Date:  2007-09-20       Impact factor: 11.598

View more
  37 in total

Review 1.  The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

2.  Meeting report: nuclear receptors: transcription factors and drug targets connecting basic research with translational medicine.

Authors:  Jan Tuckermann; William Bourguet; Susanne Mandrup
Journal:  Mol Endocrinol       Date:  2010-06-02

Review 3.  Histone arginine methylation.

Authors:  Alessandra Di Lorenzo; Mark T Bedford
Journal:  FEBS Lett       Date:  2010-11-11       Impact factor: 4.124

Review 4.  Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.

Authors:  Stéphanie Bianco; Nicolas Gévry
Journal:  Transcription       Date:  2012-07-01

Review 5.  Estrogen signaling and cardiovascular disease.

Authors:  Elizabeth Murphy
Journal:  Circ Res       Date:  2011-09-02       Impact factor: 17.367

6.  Estrogen Receptor α Is Required for Maintaining Baseline Renin Expression.

Authors:  Ko-Ting Lu; Henry L Keen; Eric T Weatherford; Maria Luisa S Sequeira-Lopez; R Ariel Gomez; Curt D Sigmund
Journal:  Hypertension       Date:  2016-02-29       Impact factor: 10.190

Review 7.  Role of PRMTs in cancer: Could minor isoforms be leaving a mark?

Authors:  R Mitchell Baldwin; Alan Morettin; Jocelyn Côté
Journal:  World J Biol Chem       Date:  2014-05-26

Review 8.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

9.  Using unnatural amino acid mutagenesis to probe the regulation of PRMT1.

Authors:  Heather L Rust; Venkataraman Subramanian; Graham M West; Douglas D Young; Peter G Schultz; Paul R Thompson
Journal:  ACS Chem Biol       Date:  2014-01-06       Impact factor: 5.100

Review 10.  Liganded and unliganded activation of estrogen receptor and hormone replacement therapies.

Authors:  Adriana Maggi
Journal:  Biochim Biophys Acta       Date:  2011-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.